Exploration of the Optimal Dosage of Cetirizine in the Treatment of Allergic Diseases in Chinese Children

Launched by PEKING UNIVERSITY THIRD HOSPITAL · Feb 24, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring the best dosage of cetirizine, a medication used to treat allergic diseases, in Chinese children. The researchers want to understand how cetirizine works in children's bodies when they have conditions like eczema, asthma, or allergic rhinitis, which is commonly known as hay fever. The study is currently looking for participants, specifically children aged between 8 and 17 years who need this medication and have not taken any other allergy medicines in the last three days.

To participate, children need to have a confirmed diagnosis of an allergic disease and their guardians must provide consent. There are some health conditions that would exclude a child from participating, such as serious liver or kidney problems, certain electrolyte imbalances, or a history of severe reactions to cetirizine. If eligible, participants will receive cetirizine and will be monitored throughout the study to help determine the most effective dosage for treating allergies in children. This trial aims to improve treatment options for young patients with allergic diseases.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. The informed consent form was voluntarily signed by the legal guardians of the subjects (children aged ≥8 years should participate in the informed consent process and sign the informed consent form).
• • 2. Pediatric patients, whether they are outpatients or inpatients, who require oral cetirizine therapy.
• • 3. The children was clinically diagnosed with allergic diseases such as eczema, urticaria, asthma, and allergic rhinitis.
• • 4. Pediatric patients had not taken other antiallergic drugs 72 hours before screening.
• Exclusion Criteria:
• • 1. Abnormal liver function (ALT or AST \> 2 times the upper limit of normal).
• • 2. Abnormal renal function (serum creatinine above the upper limit of normal or GFR \< 10 mL/min)
• • 3. Electrolyte abnormalities (potassium or magnesium \< 0.8 times lower limit of normal, \> 1.2 times upper limit of normal)
• • 4. Children who were allergic to cetirizine or had a history of serious adverse reactions.
• • 5. Pediatric patients with unstable vital signs.